About: Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 29 October 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2007 (uk) im Oktober 2007 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 29 October 2007 (en) artículu científicu espublizáu n'ochobre de 2007 (ast)
publication date	wds:Q81515023-ABA98F1F-1E72-4B8D-8222-D64B6E1FA7E4
publication date	2007-10-29 00:00:00Z (xsd:dateTime)
author name string	wds:Q81515023-13468895-E635-4FFB-896C-0D18BDF8E989 wds:Q81515023-1D8F7BF9-1D34-4247-A743-D8F3AB8C2006 wds:Q81515023-321D71AA-B287-4E55-9874-D13BDBBEBE0F wds:Q81515023-3CAF4A32-7A47-4831-9C75-985675124867 wds:Q81515023-3E9B24DC-1CCA-4830-BF1E-8E0D0DEC94E0 wds:Q81515023-7D9B8CA3-ED00-4AFB-887C-97194C329FCA wds:Q81515023-82776027-DA90-4FC1-8A56-1C5FC9F841C5 wds:Q81515023-872B3751-57CD-4D4D-ACDA-85A3DAB9A1E1 wds:Q81515023-8D12B24A-49E8-4CC6-B9D3-65C7FD6C7542 wds:Q81515023-A2823005-7DEF-4E58-9AC6-12C46AE89A30 wds:Q81515023-A586AAE1-C423-47F7-8A26-B1075CB95325 wds:Q81515023-B7FB2CC4-7846-44B6-842D-A54A1814E2EF
author name string	Burmester G Schneider M Braun J Zeidler H Krause A Sieper J Listing J Fritz C Sörensen H Baraliakos X Schewe S Alten R
rdfs:label	Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (en) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (nl)
skos:prefLabel	Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (en) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (nl)
name	Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (en) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (nl)
title	wds:Q81515023-CF47B93A-CA0C-4A99-9732-16A2B334E95A
title	Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (en)
page(s)	wds:Q81515023-AEF3999E-D1A0-4056-BAF7-4F550B2EB222
page(s)	340-345
instance of	wds:Q81515023-48F54860-A7C7-46D9-87F9-D2B920EFB95C
instance of	scholarly article
main subject	wds:Q81515023-91E0FB51-65C8-4C42-86B8-8A57E747D6AB
main subject	ankylosing spondylitis
PubMed ID	wds:Q81515023-589371A1-C53B-44F2-9733-73891D0C0F5A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17967831
PubMed ID	17967831
published in	wds:Q81515023-3E43E3C3-4713-48A0-BADF-0FC62069C935
published in	Annals of the Rheumatic Diseases
issue	wds:Q81515023-220E8C28-6CB8-451A-AA19-9751F53E51A3
volume	wds:Q81515023-9BBD9515-463B-4166-A543-D64EBE548BD8
issue	3
volume	67
DOI	wds:Q81515023-2D29B601-6C1C-436E-86B5-9AC76D870DE1
DOI	http://dx.doi.org/10.1136/ARD.2007.075879
DOI	10.1136/ARD.2007.075879
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q81515023
is cites work of	Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? Adverse effects of biologics: a network meta-analysis and Cochrane overview Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population What is the future of targeted therapy in rheumatology: biologics or small molecules? Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Infliximab: 12 years of experience A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis Spondyloarthritides: evolving therapies Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future Prevalence and characteristics of lung involvement on high resolution computed tomography in patients with ankylosing spondylitis: a systematic review. Valuing treatment with infliximab for ankylosing spondylitis using a willingness-to-pay approach Concurrent Intervention With Exercises and Stabilized Tumor Necrosis Factor Inhibitor Therapy Reduced the Disease Activity in Patients With Ankylosing Spondylitis: A Meta-Analysis Update on biologic therapy in the management of axial spondyloarthritis Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. The Bath metrology index as assessed by a trained and an untrained rater in patients with spondylarthropathy: a study of intra- and inter-rater agreements [Spondyloarthritides] Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab Inter-rater reliability of clinical mobility measures in ankylosing spondylitis The synovio-entheseal complex in enthesoarthritis Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study Impact of biological therapy on spondyloarthritis [Ankylosing spondylitis. Target treatment criteria] [Recommendations for use of rituximab in patients with rheumatoid arthritis] Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice. Management of ankylosing spondylitis with infliximab Clinical observations programme in SpA: disease parameters, treatment options and practical management issues Clinical and radiographic response to a local infliximab injection in a patient with chronic sacroiliitis. Current issues in pediatric inflammatory bowel disease-associated arthropathies The treatment of psoriatic arthritis and inflammatory spondylitis Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
is cites work of	wds:Q36633205-F48872D7-E151-47AC-90E4-0EE66734BD59 wds:Q38748204-23E3A55B-AD9A-4714-AC24-D0DE579A769D

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software